



Obesity Medicine Approach

Part 2: Treatment

Nutrition, Physical
Activity and Medications

Foundation of Energy Balance



Nutrition

What is a calorie



Amount of heat required to raise the temp of 1g of H₂O by 1C (14.5 to 15.5)



Measure of energy



1C = kcal = 1000 cal

Macronutrients

Carbohydrates

- 4 kcal/gram
- RDA 130g

Protein

- 4kcal/gram
- RDA 56g-Males 46g-Females
- Wt Maint - 0.7-1gm/kg
- Wt loss - 1.2-1.5g/kg

Fats

- 9kcal/gram
- RDA omega6=7-17g
- RDA omega3 = 0.5-1.6g

Alcohol

- 7kcal/gram

Micronutrient def post surgery

- ▶ Thiamine (B1)
 - ▶ Wet and dry beriberi
- ▶ Cyanocobalamin (B12)
 - ▶ Pernicious anemia
 - ▶ Subacute combined degeneration of the spinal cord
- ▶ Iron
 - ▶ Check ferritin
 - ▶ All bariatric patients on a multivitamin with Iron
 - ▶ 20-30% will need parenteral
- ▶ Vitamin D
 - ▶ Osteomalacia, fatigue
 - ▶ So common because a fat soluble vitamin

Others to know about

- Vitamin A
- Vitamin C
- Copper
- Vitamin K
- Vitamin E
- Zinc
- *consider anatomy and where nutrients are absorbed based on the procedure done

Sites of nutrient absorption

- ▶ Duodenum
 - ▶ Iron
 - ▶ Calcium
 - ▶ Received food, bile and digestive enzymes, neutralizes stomach acid
- ▶ Jejunum
 - ▶ Carbs, amino acids, vitamins, K
 - ▶ Absorbs iron and Ca in upper portion
- ▶ Ileum
 - ▶ Water, K, minerals, salts, fats, remaining nutrients
- ▶ Colon
 - ▶ Vitamin K, Biotin, B12, thiamine, riboflavin, water, Na, Cl
 - ▶ Secretes K and Bicarb

Nutrition Plans

Nutrition Types



Calorie Restricted

Balanced deficit diet

Meal replacements are a type of calorie restriction



Timing

Intermittent - 16-18h or longer (24-72+)

ADF (5/2)



Macronutrient Driven

High protein, low carb and fat usually

Restricting certain nutrients (Keto)



Glycemic Index

Limit foods with high glycemic index or high glycemic load

Proven for weight maintenance

Balanced

Calorie intake usually 800-1800 cal/day

I use $BMR * 0.8$ and round to get calorie goal

Then use height and ref weight to calculate protein intake (this is just a chart)

Calculate rest of macronutrients from there

Typically 35% protein, 30% fat, 30-35% carb

Use DM exchange list for meal planning

| | | |
|-------|---------|--------|
| 4'11" | 111-123 | 69-96 |
| 5'0 | 113-126 | 69-96 |
| 5'1 | 115-129 | 69-96 |
| 5'2 | 118-132 | 69-96 |
| 5'3 | 121-135 | 69-102 |
| 5'4 | 124-138 | 69-102 |
| 5'5 | 127-141 | 70-108 |
| 5'6 | 130-144 | 70-111 |
| 5'7 | 133-147 | 72-111 |
| 5'8 | 136-150 | 72-114 |
| 5'9 | 139-153 | 75-116 |
| 5'10 | 142-156 | 76-120 |
| 5'11 | 145-159 | 78-123 |
| 6'0 | 148-162 | 80-125 |

- ▶ Womens reference weight and protein goals by height
- ▶ Reference weight should not be a goal weight

| | | |
|------|---------|--------|
| 5'2 | 131-140 | 69-108 |
| 5'3 | 133-143 | 70-110 |
| 5'4 | 135-145 | 72-111 |
| 5'5 | 137-148 | 74-112 |
| 5'6 | 139-151 | 74-115 |
| 5'7 | 142-154 | 75-118 |
| 5'8 | 145-157 | 78-122 |
| 5'9 | 148-160 | 80-123 |
| 5'10 | 151-163 | 81-125 |
| 5'11 | 154-166 | 83-129 |
| 6'0 | 157-170 | 86-132 |
| 6'1 | 160-174 | 87-134 |
| 6'2 | 164-178 | 89-136 |
| 6'3 | 167-182 | 91-138 |
| 6'4 | 171-187 | 93-140 |

► Mens reference weights
and protein goals by height

Very Low Carb

No evidence <30g better than <50g

No external glucose load → use fat to make glucose (ketogenesis)

Can follow plan (keto, atkins, etc) or just eat under 50g

Watch drinks

NET CARBS AREN'T REAL - they are a calculated tool that can be used but know what they are tracking and goals

Meal Replacement


Very low calorie diet - typically under 800 cal

Protein 75-105g; carbs 50-100g; fat 10-20g

“protein sparing modified fast”

Have to watch electrolytes, gallstones

Best evidence in studies → no human error



- Thermal Effect of Food - whole food takes more to digest
- Very low calorie will often cause a natural decline in NEAT (unconscious NEAT)
- Nutrition is impacting the other side of the equation (Energy Intake)

Nutrition Impacts

Physical Activity

Physical Activity

- ▶ Physical activity is any movement (EE+NEAT)
- ▶ Exercise is a planned activity
- ▶ Increases total blood volume, ventricular compliance, venous return, EF, stroke volume, cardiac output
- ▶ Reduces risk of CVD, cancers more than any other intervention (90mins/week)

Physical Activity Guidelines




MUSCLE STRENGTHENING 2 OR MORE
DAYS PER WEEK



ADULTS - AT LEAST 150 - 300 MINS
A WEEK OF MODERATE INTENSITY,
OR 75 -150 MINS A WEEK OF
VIGOROUS INTENSITY AEROBIC
PHYSICAL ACTIVITY

Physical Activity Rx

- (F)requency
- (I)ntensity
- (T)ime
- (T)ype
- (E)njoyment
- (S)pecific
- (M)easurable
- (A)ttainable
- (R)ealistic
- (T)ime oriented



- EE - watch calorie trackers - overestimate by about 30%
- NEAT - trackers can be helpful (10,000 steps)
- RMR - indirectly affected by creation of muscle from exercise


Physical Activity Impacts

Medications

- ▶ Weight loss causes a complex set of neuroendocrine adaptations that become more intense with greater weight loss. These work to slow, and eventually halt weight loss and may induce weight gain
- ▶ Pts who have lost weight find it very difficult to resist neuroendocrine physiology with diet and behavior modification alone
- ▶ Anti-obesity Medications (AOM) help offset the physiologic adaptations that resist weight loss and promote weight gain



Why use medications?



- ▶ Short Term - phentermine (12w), diethylpropion, phendimetrazine
- ▶ Long Term - Orlistat, Qsymia, Contrave, Saxenda, Wegovy, Zepbound

FDA approvals

- ▶ Perception that obesity is a disorder of willpower
- ▶ Failure to perceive obesity as a chronic incurable disease that requires lifelong intervention has resulted in perception that weight regain after stopping meds is due to failure of the med
- ▶ Regulatory bodies (FDA, etc)
- ▶ Inadequate funding for clinical work in obesity
- ▶ Lack of medication coverage by health plans

Barriers to the use of AOM

Meds FDA approved short term

Sympathomimetics

Phentermine

Diethylpropion

Phendimetrazine

Phentermine

| | | |
|----|---|---|
| + | <ul style="list-style-type: none">Increased hungerLow BMR | Mechanism of Action: -inhibits Na-dependent NE transporter, reduces NE uptake -inhibits serotonin and dopamine reuptake |
| CI | <ul style="list-style-type: none">Active CVDPoorly controlled HTNHyperthyroidismglaucoma | |
| | | Dosing -15-30mg caps, 37.5mg tab QD-BID -8mg TID |
| | | Advice/precautions -schedule IV controlled substance -monitor BP, be aware of caffeine intake -NO evidence of addiction, withdrawal -NO established relationship to cardiac valvulopathy or pHTN |

FDA approved for long term use

Orlistat

- Xenical (1999)
- Alli (2007)

Bupropion/Naltrexone ER

- Contrave (2014)

Phentermine/Topirimate ER

- Qsymia (2012)

GLP1s

- Saxenda (liraglutide- 2014)
- Wegovy (semaeglutide - 2021)
- Zepbound (tirzepatide -2024)

Orlistat

| | | |
|----|---|--|
| + | <ul style="list-style-type: none">• Hyperlipidemia• Low risk med | Mechanism of Action: -pancreatic lipase inhibitor - blocks about 30% of fat intake |
| CI | <ul style="list-style-type: none">• Cholestasis• Chronic malabsorption syndrome | |
| | | Dosing -start: 120mg daily Range - 120mg/d - 120mg TID Alli is OTC and 60mg |
| | | Advice/precautions -advise daily multivitamin -monitor fat-soluble vitamins (ADEK) -decrease levels of cyclosporine if co-administered -no casual relationship with liver failure |
| AE | <ul style="list-style-type: none">• Flatulence• Diarrhea• Bloating• Cramping• Abdominal pain• Inc urinary oxalate• Fat soluble vitamin deficiency | |

Phentermine/Topirimate ER - QSYMIA

| | | |
|----|---|--|
| + | <ul style="list-style-type: none">• Increased hunger• Mild SE with phentermine• Non child bearing | Mechanism of Action: <ul style="list-style-type: none">-inhibits Na-dependent NE transporter, reduces NE uptake-inhibits serotonin and dopamine reuptake-TOP: AMPA, GABA receptor - decreases cravings |
| CI | <ul style="list-style-type: none">• Active CVD• Poorly controlled HTN• Hyperthyroidism• Glaucoma• Kidney stones• During or within 1d of MAOI | Dosing <ul style="list-style-type: none">-start 3.75/23mg x14d then 7.5/46mgRange: 3.75/23mg - 15/92mg/d |
| AE | <ul style="list-style-type: none">• Dry mouth, constipation, HA, palps, insomnia• Paresthesias, dysgeusia, somnolence, cognitive impairment | Advice/precautions <ul style="list-style-type: none">-schedule IV controlled substance-monitor BP, be aware of caffeine intake-rule out pregnancy before starting-increase hydration-1/4c lemon/lime juice for paresthesias |

Bupropion/Naltrexone ER (Contrave)

| | | |
|----|--|--|
| + | <ul style="list-style-type: none">• Increased hunger and cravings• Patients who smoke• On bup already | Mechanism of Action: <ul style="list-style-type: none">-reuptake inhibitor DA and NE activity increases POMC-Naltrexone blocks B-endorphin, POMC autoinhibitor Dosing <ul style="list-style-type: none">-90mg/8mg caps-1 cap x1w, 1 BID x1w, 2qAM, 1PM x1w then 2 BID |
| CI | <ul style="list-style-type: none">• seizures• Poorly controlled HTN• bulimia• Chronic opioid use | |
| AE | <ul style="list-style-type: none">• Neuropsychiatric rxns, suicidal thoughts and behavior• Nausea• HA• Insomnia• Dizziness• Dry mouth | Advice/precautions <ul style="list-style-type: none">-avoid opioids - ask about surgery-results of LIGHT trial (2017) do not show reduction in CV events-avoid in high fat diet (increases bioavailability) |

Liraglutide (Saxenda)

| | | |
|----|--|---|
| + | <ul style="list-style-type: none">• DM or preDM• Pts wit insurance coverage | Mechanism of Action: -GLP1 receptor agonist -increases satiety, decreases gastric emptying -97% homologous to human GLP1 |
| CI | <ul style="list-style-type: none">• Medullary thyroid Ca (incl fam hx)• MEN type II• Hx pancreatitis | |
| AE | <ul style="list-style-type: none">• Nausea• HA• Pancreatitis• Hypoglycemia if used with other DM agents | Dosing -start 0.6mg subq daily, titrate to 3mg daily Advice/precautions -nausea may improve with time -NO data to support increased risk of pancreatic cancer -generic liraglutide now available |

Semaglutide (Wegovy)


| | | |
|-----------|---|---|
| + | <ul style="list-style-type: none">DM or preDMCVD/PADCKDPts wit insurance coverage | Mechanism of Action: <ul style="list-style-type: none">-GLP1 receptor agonist once weekly-increases satiety, decreases gastric emptying-97% homologous to human GLP1 |
| CI | <ul style="list-style-type: none">Medullary thyroid Ca (incl fam hx)MEN type IIHx pancreatitis | |
| AE | <ul style="list-style-type: none">NauseaHAGERDPancreatitisHypoglycemia if used with other DM agents | Advice/precautions <ul style="list-style-type: none">-nausea may improve with time-discuss smaller meal portions |

Wegovy at dose 2.4mg/week (packet insert)

| | Study 1 (Obesity or overweight with comorbidity) | | Study 2 (Type 2 diabetes with obesity or overweight) | | Study 3 (Obesity or overweight with comorbidity undergoing intensive lifestyle therapy) | |
|---|--|--------------------------|--|-----------------------|---|-------------------------|
| Intention-to-Treat ^a | PLACEBO N = 655 | WEGOVY N = 1306 | PLACEBO N = 403 | WEGOVY N = 404 | PLACEBO N = 204 | WEGOVY N = 407 |
| Body Weight | | | | | | |
| Baseline mean (kg) | 105.2 | 105.4 | 100.5 | 99.9 | 103.7 | 106.9 |
| % change from baseline (LSMean) | -2.4 | -14.9 | -3.4 | -9.6 | -5.7 | -16.0 |
| % difference from placebo (LSMean) (95% CI) | | -12.4 (-13.3; -11.6)* | | -6.2 (-7.3; -5.2)* | | -10.3 (-11.8; -8.7)* |
| % of Patients losing greater than or equal to 5% body weight | 31.1 | 83.5 | 30.2 | 67.4 | 47.8 | 84.8 |
| % difference from placebo (LSMean) (95% CI) | | 52.4 (48.1; 56.7)* | | 37.2 (30.7; 43.8)* | | 37.0 (28.9; 45.2)* |
| % of Patients losing greater than or equal to 10% body weight | 12.0 | 66.1 | 10.2 | 44.5 | 27.1 | 73.0 |
| % difference from placebo (LSMean) (95% CI) | | 54.1 (50.4; 57.9)* | | 34.3 (28.4; 40.2)* | | 45.9 (38.0; 53.7)* |
| % of Patients losing greater than or equal to 15% body weight | 4.8 | 47.9 | 4.3 | 25.1 | 13.2 | 53.4 |
| % difference from placebo (LSMean) (95% CI) | | 43.1 (39.8; 46.3)* | | 20.7 (15.7; 25.8)* | | 40.2 (33.1; 47.3)* |

Tirzepatide (Zepbound)

| | | |
|----|--|---|
| + | <ul style="list-style-type: none">• DM or preDM• OSA• Pts wit insurance coverage | Mechanism of Action: -GLP1 and GIP receptor agonist -increases satiety, slows gastric emptying |
| CI | <ul style="list-style-type: none">• Medullary thyroid Ca (incl fam hx)• MEN type II• Hx pancreatitis• Suicide attempt | |
| AE | <ul style="list-style-type: none">• Nausea• HA• Pancreatitis• Hypoglycemia if used with other DM agents | Dosing -start 2.5mg weekly, titrate after 4w at each dose Advice/precautions -nausea may improve with time |



- Energy Intake decrease

Medication Impacts

Other things that affect the equation

- ▶ RMR: MUSCLE!!!! When muscle mass is controlled for, RMR does not change drastically with age or gender
- ▶ RMR: caffeine, supplements (fish oil) can increase but often give you acute increase and if you don't use that energy it will compensate and decrease
- ▶ RMR: SLEEP!!!! Huge chronic part of the equation
- ▶ TEF: The way you prepare food